Journey East: How Chinese Returnees Build Global-Bound Biopharmas
From Money To Talent To Collaboration, Challenges Keep Coming
Executive Summary
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
You may also be interested in...
Hotter Than Oncology? China Immunology Players Raise $650m
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.
China Closes In On Top 10 In Global Innovation Ranking
China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.
China Drug Price Negotiations: Another Race To The Bottom？
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?